{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:17:35Z","timestamp":1787314655684,"version":"build-2736575974"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["29854-2023"],"award-info":[{"award-number":["29854-2023"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008644","name":"McGill University Faculty of Medicine and Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-180368"],"award-info":[{"award-number":["PJT-180368"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["PC220307"],"award-info":[{"award-number":["PC220307"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.gene.2025.149774","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:34:31Z","timestamp":1758620071000},"page":"149774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications"],"prefix":"10.1016","volume":"972","author":[{"given":"Luisa","family":"Bacca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Brandariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-8765","authenticated-orcid":false,"given":"David P.","family":"Labb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0005","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"42","key":"10.1016\/j.gene.2025.149774_b0010","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1002\/anie.201204663","article-title":"Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles","volume":"51","author":"Agostini","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"24","key":"10.1016\/j.gene.2025.149774_b0015","doi-asserted-by":"crossref","first-page":"13742","DOI":"10.1073\/pnas.93.24.13742","article-title":"Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts","volume":"93","author":"Alcorta","year":"1996","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI40535","article-title":"A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis","volume":"120","author":"Alimonti","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"8004","key":"10.1016\/j.gene.2025.149774_b0025","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1038\/s41586-024-07197-3","article-title":"Author correction: Senolytic CAR T cells reverse senescence-associated pathologies","volume":"627","author":"Amor","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0030","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.onc.1209830","article-title":"Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor","volume":"26","author":"An","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","article-title":"Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors","volume":"36","author":"Araujo","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.gene.2025.149774_b0045","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.gene.2025.149774_b0050","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12935-022-02677-w","article-title":"Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets","volume":"22","author":"Asgharian","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.gene.2025.149774_b0060","article-title":"Induction of cellular senescence by androgen receptor agonist or antagonist is mediated via two novel common DYRK1A-DREAM and cyclin G2 signaling pathways in castration-resistant prostate cancer","author":"Atri Roozbahani","year":"2025","journal-title":"J. Adv. Res."},{"issue":"24","key":"10.1016\/j.gene.2025.149774_b0065","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, a dual Inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"48","key":"10.1016\/j.gene.2025.149774_b0070","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/onc.2015.41","article-title":"CCAAT\/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells","volume":"34","author":"Barakat","year":"2015","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-11-0061","article-title":"Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation","volume":"10","author":"Barreto-Andrade","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejps.2012.12.003","article-title":"Overview of the therapeutic potential of piplartine (piperlongumine)","volume":"48","author":"Bezerra","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"23\u201324","key":"10.1016\/j.gene.2025.149774_b0085","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0022-2836(78)90294-2","article-title":"A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena","volume":"120","author":"Blackburn","year":"1978","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172048","article-title":"Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy","volume":"12","author":"Blute","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2025.149774_b0100","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-24-0903","article-title":"Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4\/6 inhibitors in prostate cancer","author":"Brandariz","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0105","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068003","article-title":"Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells","volume":"8","author":"Burton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2025.149774_b0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2021.09.037","article-title":"Prostate cancer dormancy and recurrence","volume":"524","author":"Cackowski","year":"2022","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0120","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41422-020-0314-9","article-title":"Elimination of senescent cells by beta-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.gene.2025.149774_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114765","article-title":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","volume":"193","author":"Carpenter","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0130","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","article-title":"Cellular senescence and senolytics: the path to the clinic","volume":"28","author":"Chaib","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060408","article-title":"PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells","volume":"8","author":"Chatterjee","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0140","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0145","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.7150\/thno.71360","article-title":"Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0150","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/sj.onc.1207284","article-title":"Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3","volume":"23","author":"Chendil","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13578-023-01157-6","article-title":"The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment","volume":"13","author":"Cheng","year":"2023","journal-title":"Cell Biosci."},{"issue":"12","key":"10.1016\/j.gene.2025.149774_b0160","first-page":"3920","article-title":"A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer","volume":"7","author":"Chi","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.gene.2025.149774_b0165","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with Metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0170","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.15252\/embr.201439245","article-title":"Senescence and apoptosis: dueling or complementary cell fates?","volume":"15","author":"Childs","year":"2014","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0175","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/pros.23766","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation","volume":"79","author":"Choi","year":"2019","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.gene.2025.149774_b0180","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2025.149774_b0185","unstructured":"ClinicalTrials.gov. Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer [ClinicalTrials.gov Identifier: NCT01828476]: Rutgers, The State University of New Jersey; 2017 [Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT01828476."},{"key":"10.1016\/j.gene.2025.149774_b0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Coppe","year":"2010","journal-title":"Annu. Rev. Pathol."},{"issue":"9","key":"10.1016\/j.gene.2025.149774_b0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.trecan.2024.06.005","article-title":"Metastatic hormone-naive prostate cancer: a distinct biological entity","volume":"10","author":"Corres-Mendizabal","year":"2024","journal-title":"Trends Cancer."},{"issue":"20","key":"10.1016\/j.gene.2025.149774_b0200","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/sj.onc.1210950","article-title":"Many roads lead to oncogene-induced senescence","volume":"27","author":"Courtois-Cox","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0205","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrc2440","article-title":"Living on a break: cellular senescence as a DNA-damage response","volume":"8","author":"d'Adda di Fagagna","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0210","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-21-4302","article-title":"A phase Ib\/II study of the CDK4\/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer","volume":"28","author":"de Kouchkovsky","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"7525","key":"10.1016\/j.gene.2025.149774_b0215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer","volume":"515","author":"Di Mitri","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.gene.2025.149774_b0220","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","article-title":"A biomarker that identifies senescent human cells in culture and in aging skin in vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clgc.2019.02.010","article-title":"Randomized phase II trial of abiraterone alone or with dasatinib in men with Metastatic Castration-resistant Prostate Cancer (mCRPC)","volume":"17","author":"Dorff","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0230","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"issue":"20","key":"10.1016\/j.gene.2025.149774_b0235","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"Ewald","year":"2010","journal-title":"J. Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.22571","article-title":"Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo","volume":"73","author":"Ewald","year":"2013","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of SASP in cancer","volume":"19","author":"Faget","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0250","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1349-7006.2012.02272.x","article-title":"Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis","volume":"103","author":"Fang","year":"2012","journal-title":"Cancer Sci."},{"issue":"10336","key":"10.1016\/j.gene.2025.149774_b0255","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0260","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0265","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cam4.553","article-title":"Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis","volume":"5","author":"Frame","year":"2016","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0275","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1091\/mbc.e11-10-0884","article-title":"Lamin B1 loss is a senescence-associated biomarker","volume":"23","author":"Freund","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0280","first-page":"1233","article-title":"Androgen deprivation therapy affects BCL-2 expression in human prostate cancer","volume":"39","author":"Fuzio","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0285","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.18632\/aging.100527","article-title":"Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. a method applicable in cryo-preserved and archival tissues","volume":"5","author":"Georgakopoulou","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.gene.2025.149774_b0295","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gene.2025.149774_b0300","doi-asserted-by":"crossref","unstructured":"Gillessen S, L.R. M, N.D. J, A. S, G. A, R.J. J, et al. LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE. In: Committee ECS, editor. ESMO Congress 2024; Barcelona Gran Via2024.","DOI":"10.1016\/j.annonc.2024.08.2313"},{"key":"10.1016\/j.gene.2025.149774_b0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/nu11102376","article-title":"Curcumin and Cancer","volume":"11","author":"Giordano","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0310","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13142","article-title":"Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity","volume":"19","author":"Gonzalez-Gualda","year":"2020","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0315","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular Senescence: defining a Path Forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"issue":"69","key":"10.1016\/j.gene.2025.149774_b0320","doi-asserted-by":"crossref","first-page":"113792","DOI":"10.18632\/oncotarget.22776","volume":"8","author":"Gravina","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0325","doi-asserted-by":"crossref","first-page":"R178","DOI":"10.1016\/S0960-9822(98)70105-8","article-title":"Telomeres and senescence: the history, the experiment, the future","volume":"8","author":"Greider","year":"1998","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0330","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","article-title":"Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis","volume":"39","author":"Guccini","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0335","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13133","article-title":"Galactose-modified duocarmycin prodrugs as senolytics","volume":"19","author":"Guerrero","year":"2020","journal-title":"Aging Cell"},{"issue":"7989","key":"10.1016\/j.gene.2025.149774_b0340","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"issue":"3\u20134","key":"10.1016\/j.gene.2025.149774_b0345","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12672-020-00391-5","article-title":"Interleukin-23 represses the level of cell senescence induced by the androgen receptor antagonists enzalutamide and darolutamide in castration-resistant prostate cancer cells","volume":"11","author":"Gupta","year":"2020","journal-title":"Horm Cancer."},{"key":"10.1016\/j.gene.2025.149774_b0350","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0355","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of Cellular Senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0360","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI95148","article-title":"Mechanisms and functions of cellular senescence","volume":"128","author":"Herranz","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0365","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1210\/me.2014-1170","article-title":"A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells","volume":"28","author":"Hessenkemper","year":"2014","journal-title":"Mol. Endocrinol."},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0370","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0375","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","article-title":"Cellular senescence: the good, the bad and the unknown","volume":"18","author":"Huang","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0380","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","article-title":"BH3-only proteins-essential initiators of apoptotic cell death","volume":"103","author":"Huang","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/fsn3.1872","article-title":"Fisetin: an anticancer perspective","volume":"9","author":"Imran","year":"2021","journal-title":"Food Sci. Nutr."},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0390","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gene.2025.149774_b0395","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1196\/annals.1404.008","article-title":"Lipofuscin: formation, distribution, and metabolic consequences","volume":"1119","author":"Jung","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.gene.2025.149774_b0400","doi-asserted-by":"crossref","first-page":"10499","DOI":"10.2147\/OTT.S266085","article-title":"Novel therapeutic strategies for CDK4\/6 inhibitors in metastatic castrate-resistant prostate cancer","volume":"13","author":"Kase","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0405","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1158\/1940-6207.CAPR-20-0383","article-title":"Phase I trial of encapsulated rapamycin in patients with prostate cancer under active surveillance to prevent progression","volume":"14","author":"Kemp Bohan","year":"2021","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0410","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjc.6605178","article-title":"Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis","volume":"101","author":"Koreckij","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"7626","key":"10.1016\/j.gene.2025.149774_b0415","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.gene.2025.149774_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.645593","article-title":"Mechanisms of Cellular Senescence: Cell Cycle arrest and Senescence Associated Secretory Phenotype","volume":"9","author":"Kumari","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"Pt 20","key":"10.1016\/j.gene.2025.149774_b0425","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1242\/jcs.113.20.3613","article-title":"Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells","volume":"113","author":"Kurz","year":"2000","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0430","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1474-9726.2006.00199.x","article-title":"Senescence-associated beta-galactosidase is lysosomal beta-galactosidase","volume":"5","author":"Lee","year":"2006","journal-title":"Aging Cell"},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0435","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4161\/cbt.6.8.4544","article-title":"Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway","volume":"6","author":"Lehmann","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0440","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4161\/cc.6.5.3901","article-title":"A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells","volume":"6","author":"Lehmann","year":"2007","journal-title":"Cell Cycle"},{"issue":"19","key":"10.1016\/j.gene.2025.149774_b0445","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1158\/0008-5472.CAN-07-6538","article-title":"Senescence-associated exosome release from human prostate cancer cells","volume":"68","author":"Lehmann","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0450","doi-asserted-by":"crossref","first-page":"771","DOI":"10.18632\/aging.101787","article-title":"The curcumin analog EF24 is a novel senolytic agent","volume":"11","author":"Li","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.gene.2025.149774_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mad.2019.05.001","article-title":"Emerging senolytic agents derived from natural products","volume":"181","author":"Li","year":"2019","journal-title":"Mech. Ageing Dev."},{"issue":"9","key":"10.1016\/j.gene.2025.149774_b0460","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1158\/1078-0432.CCR-07-1490","article-title":"A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors","volume":"14","author":"Liu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0465","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-21-0604","article-title":"Olaparib-induced senescence is bypassed through G2-M checkpoint override in olaparib-resistant prostate cancer","volume":"21","author":"Lombard","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0470","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0475","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/ijbs.41686","article-title":"Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways","volume":"16","author":"Lu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0480","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm2217","article-title":"Lysosomes: fusion and function","volume":"8","author":"Luzio","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0485","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"gammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071593","article-title":"DNA damage- but not enzalutamide-induced senescence in prostate cancer promotes senolytic bcl-xl inhibitor sensitivity","volume":"9","author":"Malaquin","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0495","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clgc.2018.12.009","article-title":"Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (metab-pro): phase 2 pilot study","volume":"17","author":"Mark","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0500","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41388-021-02060-5","article-title":"The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells","volume":"41","author":"Mirzakhani","year":"2022","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0505","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/acel.12075","article-title":"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK\/NF-kappaB activation","volume":"12","author":"Moiseeva","year":"2013","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0510","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13046-023-02769-z","article-title":"A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer","volume":"42","author":"Mourkioti","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0515","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/pros.20303","article-title":"Antisense Bcl-2 sensitizes prostate cancer cells to radiation","volume":"65","author":"Mu","year":"2005","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.gene.2025.149774_b0520","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1535-7163.MCT-16-0515","article-title":"Fisetin enhances chemotherapeutic effect of cabazitaxel against human prostate cancer cells","volume":"15","author":"Mukhtar","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0525","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: from physiology to pathology","volume":"15","author":"Munoz-Espin","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0530","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.3892\/ijo.2016.3482","article-title":"Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells","volume":"48","author":"Ogura","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.gene.2025.149774_b0535","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2018.03.007","article-title":"BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy","volume":"423","author":"Oing","year":"2018","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0540","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/1878-0261.12807","article-title":"Cellular senescence in cancer: from mechanisms to detection","volume":"15","author":"Ou","year":"2021","journal-title":"Mol. Oncol."},{"issue":"24","key":"10.1016\/j.gene.2025.149774_b0545","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244026","article-title":"Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer","volume":"11","author":"Pardella","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.gene.2025.149774_b0550","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5054","article-title":"Results from a phase Ib\/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC). 2019 ASCO annual meeting I","author":"Parikh","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.gene.2025.149774_b0555","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins","volume":"51","author":"Park","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.gene.2025.149774_b0560","article-title":"Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer","author":"Perimbeti","year":"2025","journal-title":"medRxiv"},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0565","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1593\/neo.11182","article-title":"Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2","volume":"13","author":"Pernicova","year":"2011","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0570","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/pros.23843","article-title":"Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide","volume":"79","author":"Pilling","year":"2019","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0575","doi-asserted-by":"crossref","first-page":"20358","DOI":"10.1038\/s41598-021-99852-2","article-title":"Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker","volume":"11","author":"Poblocka","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0580","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clgc.2021.08.008","article-title":"TAXOMET: a french prospective multicentric randomized phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer","volume":"19","author":"Pujalte Martin","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.gene.2025.149774_b0585","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13578-020-00422-2","article-title":"Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells","volume":"10","author":"Pungsrinont","year":"2020","journal-title":"Cell Biosci."},{"issue":"19","key":"10.1016\/j.gene.2025.149774_b0590","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/jcmm.17923","article-title":"Androgen receptor agonist and antagonist reduce response of cytokine-induced killer cells on prostate cancer cells","volume":"27","author":"Pungsrinont","year":"2023","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0595","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0600","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate Cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0605","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","article-title":"AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies","volume":"15","author":"Rhyasen","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0610","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP inhibitors and prostate cancer: to infinity and beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.gene.2025.149774_b0615","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1476-4598-13-214","article-title":"Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway","volume":"13","author":"Roediger","year":"2014","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0360-3016(02)04468-1","article-title":"Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma","volume":"56","author":"Rosser","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0625","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cellsig.2011.12.006","article-title":"Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP)","volume":"24","author":"Salminen","year":"2012","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0630","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0635","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cac2.12636","article-title":"Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein","volume":"45","author":"Shao","year":"2025","journal-title":"Cancer Commun (Lond)."},{"key":"10.1016\/j.gene.2025.149774_b0640","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/bs.acr.2021.01.006","article-title":"Autophagy and PTEN in DNA damage-induced senescence","volume":"150","author":"Sharma","year":"2021","journal-title":"Adv. Cancer Res."},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0645","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.gene.2025.149774_b0650","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1101\/gad.179515.111","article-title":"The role of nuclear lamin B1 in cell proliferation and senescence","volume":"25","author":"Shimi","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.gene.2025.149774_b0655","doi-asserted-by":"crossref","unstructured":"Smith MR, Piulats JM, Todenh\u00f6fer T, Lee J-L, Arranz Arija JA, Mazilu L, et al. CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. 2024 ASCO Annual Meeting I; Chicago, Illinois: Journal of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.5001"},{"issue":"12","key":"10.1016\/j.gene.2025.149774_b0660","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0665","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0670","doi-asserted-by":"crossref","first-page":"22 e5","DOI":"10.1016\/j.clgc.2020.05.013","article-title":"A phase 2 trial of abiraterone followed by randomization to addition of dasatinib or sunitinib in men with metastatic castration-resistant prostate cancer","volume":"19","author":"Spetsieris","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0675","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10637-019-00807-2","article-title":"A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors","volume":"38","author":"Stein","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"9","key":"10.1016\/j.gene.2025.149774_b0680","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B","volume":"18","author":"Sun","year":"2012","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0685","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202357265","article-title":"Lysosomes in senescence and aging","volume":"24","author":"Tan","year":"2023","journal-title":"EMBO Rep."},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0690","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.gene.2025.149774_b0695","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbrc.2023.09.032","article-title":"Doxorubicin-induced senescence promotes resistance to cell death by modulating genes associated with apoptotic and necrotic pathways in prostate cancer DU145 CD133(+)\/CD44(+) cells","volume":"680","author":"Tatar","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0700","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI64098","article-title":"Cellular senescence and the senescent secretory phenotype: therapeutic opportunities","volume":"123","author":"Tchkonia","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.gene.2025.149774_b0705","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.biocel.2003.08.009","article-title":"Lipofuscin","volume":"36","author":"Terman","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0710","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10637-015-0307-6","article-title":"A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study","volume":"34","author":"Thakur","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0715","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"issue":"15","key":"10.1016\/j.gene.2025.149774_b0720","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-03-0701","article-title":"A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer","volume":"10","author":"Tolcher","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0725","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-04-2145","article-title":"A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer","volume":"11","author":"Tolcher","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0730","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-022-29824-1","article-title":"Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer","volume":"13","author":"Troiani","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.gene.2025.149774_b0735","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"issue":"10087","key":"10.1016\/j.gene.2025.149774_b0740","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","article-title":"Advances in the treatment of advanced oestrogen-receptor-positive breast cancer","volume":"389","author":"Turner","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0745","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/CAD.0b013e328361feb0","article-title":"A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy","volume":"24","author":"Twardowski","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0750","article-title":"Senescence-associated beta-galactosidase detection in pathology","volume":"12","author":"Valieva","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0755","first-page":"645","article-title":"Potential anticancer properties and mechanisms of action of curcumin","volume":"35","author":"Vallianou","year":"2015","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0760","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"29","key":"10.1016\/j.gene.2025.149774_b0765","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","article-title":"Senescence as a therapeutically relevant response to CDK4\/6 inhibitors","volume":"39","author":"Wagner","year":"2020","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0770","first-page":"2284","article-title":"Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved","volume":"55","author":"Wang","year":"1995","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0775","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.18632\/aging.101100","article-title":"Discovery of piperlongumine as a potential novel lead for the development of senolytic agents","volume":"8","author":"Wang","year":"2016","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"10.1016\/j.gene.2025.149774_b0780","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","article-title":"Senescent cells in cancer therapy: friends or foes?","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer."},{"issue":"6","key":"10.1016\/j.gene.2025.149774_b0785","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.gene.2025.149774_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071184","article-title":"ALDH1A3 regulates cellular senescence and senescence-associated secretome in prostate cancer","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.gene.2025.149774_b0795","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"issue":"6456","key":"10.1016\/j.gene.2025.149774_b0800","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/366701a0","article-title":"p21 is a universal inhibitor of cyclin kinases","volume":"366","author":"Xiong","year":"1993","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.gene.2025.149774_b0805","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1535-7163.MCT-19-1141","article-title":"Synthetic lethal metabolic targeting of androgen-deprived prostate cancer cells with metformin","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.gene.2025.149774_b0810","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"Ying","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0815","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-020-16347-w","article-title":"The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice","volume":"11","author":"Yoshida","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2025.149774_b0820","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ebiom.2018.09.015","article-title":"Fisetin is a senotherapeutic that extends health and lifespan","volume":"36","author":"Yousefzadeh","year":"2018","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.gene.2025.149774_b0825","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0830","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0835","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/febs.16350","article-title":"Targeting cellular senescence with senotherapeutics: senolytics and senomorphics","volume":"290","author":"Zhang","year":"2023","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.gene.2025.149774_b0840","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155725","article-title":"Both complexity and location of DNA damage contribute to cellular senescence induced by ionizing radiation","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.gene.2025.149774_b0845","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles' heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0850","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"issue":"3","key":"10.1016\/j.gene.2025.149774_b0855","doi-asserted-by":"crossref","first-page":"955","DOI":"10.18632\/aging.101202","article-title":"New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463","volume":"9","author":"Zhu","year":"2017","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.gene.2025.149774_b0860","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12915-025-02172-4","article-title":"ARv7 promotes the escape of prostate cancer cells from androgen deprivation therapy-induced senescence by mediating the SKP2\/p27 axis","volume":"23","author":"Zhuang","year":"2025","journal-title":"BMC Biol."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925005633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925005633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:30:10Z","timestamp":1777566610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925005633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":172,"alternative-id":["S0378111925005633"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149774","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149774"}}